Suboptimal doses of low molecular weight heparin and acute venous thromboembolism. Data from the RIETE registry

Annals of Hematology

Volumn 86, Issue 7, 2007, Pages 519-526

  Bruscas, Ma Jesús ^a   Nieto, José Antonio ^a   Perez Pinar, Monserrat ^a   López Jiménez, Luciano ^b   Fernández Capitán, Carmen ^c   López Chuliá, Francisca ^d   Orue Lecue, Ma Teresa ^e  

^a HOSPITAL VIRGEN DE LA LUZ   (Spain)

^b HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d HOSPITAL ARNAU DE VILANOVA   (Spain)

^e Instituto de Investigación Sanitaria de Navarra   (Spain)

Author keywords

Hemorrhage; Low molecular weight heparin; Outcome; Suboptimal dose; Venous thromboembolism

Indexed keywords

BEMIPARIN; CREATININE; DALTEPARIN; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; TINZAPARIN;

ACUTE DISEASE; ADULT; AGED; ARTICLE; BLEEDING; BODY WEIGHT; CLINICAL PRACTICE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEEP VEIN THROMBOSIS; DISEASE REGISTRY; DRUG DOSE COMPARISON; FEMALE; FOLLOW UP; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECURRENCE RISK; RETROSPECTIVE STUDY; RISK FACTOR; VENOUS THROMBOEMBOLISM;

AGED; AGED, 80 AND OVER; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMORRHAGE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MIDDLE AGED; MORTALITY; PHYSICIAN'S PRACTICE PATTERNS; PULMONARY EMBOLISM; RECURRENCE; REGISTRIES; RETROSPECTIVE STUDIES; SPAIN; SURVIVAL ANALYSIS; VENOUS THROMBOSIS;

EID: 34249867404     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-007-0282-x     Document Type: Article

References (38)

1. Büller HR, Agnelli G, Hull RD, Hyers TH, Prins MH, Raskob GE (2004) Antithrombotic therapy for venous thromboembolic disease. The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126: 401S-428S
2. Hirsh J, Raschke R (2004) Heparin and low-molecular-weight heparin. The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126:188S-203S
3. Frydman AM, Bara L, Le Roux Y, Woler M, Chauliac F, Samama MM (1988) The antithrombotic activity and pharmacokinetics of enoxaparin, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80 mg. J Clin Pharmacol 28:609-618
4. Matzsch T, Bergqvist D, Hedner OR, Ostergaard P (1987) Effects of an enzymatically depolymerised heparin ace compared with conventional heparin in healthy volunteers. Thromb Haemost 57:97-101
5. Quinlan DJ, McQuillan TO, Eikelboom JW (2004) Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: A goal-analysis of randomized controlled trials. Ann Intern Med 140:175-183
6. Bratt G, Tornebohm AND, Widlund L, Lockner D (1986) Low molecular weight heparine (KABI 2165, Fragmin): Pharmacokinetics after intravenous and subcutaneous administration in human volunteers. Thromb Res 42:613-620
7. Brophy DF, Martin EJ, Best AM, Gehr TW, Carr ME (2004) Antifactor Xa activity correlates to thrombin generation cheats, platelet contactile forced and clot elastic modulus following former alive enoxaparin exposure in patients with and without renal dysfunction. Thromb Haemost 2:1299-1304
8. Bianchini P, Bergonzini GL, Parma B, Osima B (1995) Relationship between captures antifactor Xa activity and the antithrombotic activity of heparins of molecular different mass. Haemostasis 25:288-298
9. Gosselin RC, King JH, Janatpour KA, Dager WE, Larkin EC, Owings JT (2004) Variability of captures anti-Xa activities with different lots of enoxaparin. Ann Pharmacother 38:563-568
10. Greaves M (2002) Limitations of the laboratory monitoring of heparin therapy. Thromb Haemost 87:163-164
11. González-Fajardo JA, Arreba AND, Castrodeza J, Pérez JL, Fernández L, Agundez I, Mateo AM, Career S, Gutiérrez V, Cowboy C (1999) Venographic comparison of subcutaneous low-molecular weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis. J Vasc Surg 30:283-292
12. Pini M, Aiello S, Manotti C, Pattacini C, Quintavalla R, Poli T, Tagliaferri TO, Dettori AG (1994) Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thromb Haemost 72:191-197
13. Marchetti M, Pistorio TO, Barone M, Serafini S, Barosi G (2001) Low-molecular-weight Heparin versus warfarin for secondary prophylaxis of venous thromboembolism. A cost-effectiviness analysis. Am J Med 111:159-160
14. Veiga F, Scribe TO, Maluenda MP, López Rubio M, Margalet I, Lezana TO, Galician J, Riverside JM (2000) Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long-term treatment of deep venous thrombosis in the elderly: A randomized trial. Thromb Haemost 84:559-564
15. Arcelus JL, Monreal M, Caprini JA, Suarez C, González-Fajardo JA, for the RIETE investigators (2003) The management and outcome of acute venous thromboembolism: A prospective registry including 4,011 patients. J Vasc Surg 38:916-922
16. Monreal M, Súarez C, González-Fajardo JA, Barba R, Uresandi F, Valle R, Rondón P, and the RIETE Investigators (2004) Management of patients with acute venous thromboembolism: Findings from the RIETE Registry. Pathophysiol Haemost Thromb 33:330-334
17. Nieto JA, Diaz de Tuesta A, Marchena J, Tiberio G, Todoli JA, Samperiz AL y Monreal M (2005) Clinical outcome of patients with venous thromboembolism and recent major bleeding: Findings from a prospective registry (RIETE). J Thromb Haemost 3:703-709
18. Monreal M, Kakkar AK, Caprini JA, Barba R, Uresandi F, Valle R, Suárez C, Otero R, the RIETE Investigators (2004) The outcome after treatment of venous thromboembolism is different in surgical and acutely ill medical patients. Findings from the RIETE Registry. J Thromb Haemost 2:1-7
19. Wicki J, Perrier A, Perneger TV, Bounameaux H, Junod AF (2000) Predicting adverse outcome in patients with acute pulmonary embolism: A risk score. Thromb Haemost 84:548-552
20. Heit JA, Silverstein MD, Mohr DN, Petterson TM, Lohse CM, O'Fallon WM, Melton LJ (2001) The epidemiology of venous thromboembolism in the community. Thromb Haemost 86:452-463
21. Prandoni P, Lensing AWA, Piccioli A, Bernardi E, Simioni P, Girolani B, Marchiori A, Sabbion P, Prins MH, Noventa F, Girolami A (2002) Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100:3484-3488
22. Douketis JD, Foster GA, Crowther MA, Prins MH, Ginsberg JS (2000) Clinical risks factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy. Arch Intern Med 160:3431-3436
23. Kyrle PA, Minar E, Bialonczyk C, Hirschl M, Weltermann A, Eichinger S (2004) The risk of recurrent venous thromboembolism in men and women. N Engl J Med 350:2558-2563
24. Jimenez D, Diaz G, Marin E, Vidal R, Sueiro A, Yusen RD (2006) The risk of recurrent venous thromboembolism in patients with unprovoked symptomatic deep vein thrombosis and asymptomatic pulmonary embolism. Thromb Haemost 95:562-566
25. Decousus H, Leizorovicz A, Parent F, Page Y, Tardy B, Girard P, Laporte S, Faivre R, Charbonnier B, Barral FG, HUet Y, Simonneau G (1998) A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. N Engl J Med 338:409-415
26. Hansson PO, Sorbo J, Eriksson H (2000) Recurrent venous thromboembolism after deep vein thrombosis: Incidence and risk factors. Arch Intern Med 160:769-774
27. Santamaría MG, Agnelli G, Taliani MR, Prandoni P, Moia M, Bazzan M, Guazzaloca G, Agneno W, Bertoldi A, Silingardi M, Tomasi C, Ambrosio GB (2005) Thrombophilic abnormalities and recurrence of venous thromboembolism in patients treated with standardized anticoagulant treatment. Thromb Res 116:301-306
28. Wells PS, Forgie MA, Simms M, Greene A, Touchie D, Lewis G, Anderson J, Rodger MA (2003) The outpatient bleeding risk index. Validation of a tool for predicting bleeding rates in patients treated for deep venous thrombosis and pulmonary embolism. Arch Intern Med 163:917-920
29. White RH, Beyth RJ, Zhou H, Romano PS (1999) Major bleeding after hospitalization for deep vein thrombosis. Am J Med 107:414-424
30. Kuijer PMM, Hutten BA, Prins MH, Büller HR (1999) Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med 159:457-460
31. Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L (1987) Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy. Am J Med 82:703-713
32. Hull R, Raskob GE, Rosemblom D, Panju AA, Brill-Edwards P, Ginsberg JS, Hirsh J, Martín GJ, Green D (1990) Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med 322:1260-1264
33. Eriksson H, Lundstrom T, Wahlander K, Clason SB, Schulman S, THRIVE III Investigators (2005) Prognostic factors for recurrence of venous thromboembolism or bleeding during long term secondary prevention of VTE with ximelagatran. Thromb Haemost 94:522-527
34. Hull RD, Raskob GE, Rosemblom D, Lemaire J, Pineo GF, Baylis B, Ginsberg JS, Panju AA, Brill-Edwards P, Brant R (1992) Optimal therapeutic level of heparin therapy in patients with venous thrombosis. Arch Intern Med 152:1589-1595
35. Siegbahn A, Y-Hassan S, Boberg J, Bylund H, Neerstrand HS, Ostergaard P, Hedner U (1989) Subcutaneous treatment of deep venous thrombosis with low molecular weight heparin. A dose finding study with LMWH-Novo. Thromb Res 55:767-768
36. Bratt G, Tornebohm E, Widlund L, Lockner D (1986) Low molecular heparin (KABI 2165, Fragmin): Pharmacokinetics after intravenous and subcutaneous administration in human volunteers. Thromb Res 42:613-620
37. Samama MM, Gerotziafas GT (2000) Comparative pharmacokinetics of LMWHs. Semin Thromb Hemost 26:31-38
38. Siragusa S, Cosmi B, Piovella F, Hirsh J, Ginsberg JS (1996) Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: Results of a meta-analysis. Am J Med 100:269-277